ClassID:

241467

Y10S424/809 - CPC Classification

Classification description:

Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain

Recent Application in this class:
#1
20250154286
2025-05-15

ANTI-PCSK9 ANTIBODIES

#2
20230340153
2023-10-26

Anti-PCSK9 antibodies

#3
20190135941
2019-05-09

Anti-PCSK9 antibodies

#4
20180208643
2018-07-26

ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND USES THEREOF

#5
20150030617
2015-01-29

Methods of treating cancer with low density lipoprotein-related protein 6 (LRP6)—half life extender constructs

#6
20140120614
2014-05-01

Antibodies against clostridium difficile toxins and uses thereof

#7
20140050725
2014-02-20

Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs

#8
20130202592
2013-08-08

Method for inhibiting cancer metastasis by administration of the extracellular domain DLK1 or a DLK1-FC fusion protein

#9
20130084291
2013-04-04

Compositions and methods for increasing serum half-life

#10
20130053547
2013-02-28

Agonist antibody to human thrombopoietin receptor

#11
20120309936
2012-12-06

Reducing the immunogenicity of fusion proteins

#12
20120288508
2012-11-15

Antibodies against clostridium difficile toxins and uses thereof

#13
20120064063
2012-03-15

Compositions of F(ab′)antibody fragments

#14
20120053326
2012-03-01

Agonist antibody to human thrombopoietin receptor

#15
20110300143
2011-12-08

Prenatal enzyme replacement therapy for hypophosphatasia

#16
20110065902
2011-03-17

High affinity human antibodies to PCSK9

#17
20100233182
2010-09-16

Antibodies against toxins and uses thereof

#18
20100233181
2010-09-16

Antibodies against clostridium difficile toxins and uses thereof

#19
20100166768
2010-07-01

High affinity human antibodies to PCSK9

#20
20100129367
2010-05-27

Human beta-glucuronidase mutants with elevated enzymatic activity under physiological conditions and method for identifying such

#21
20100016562
2010-01-21

Reducing the immunogenicity of fusion proteins

#22
20100004429
2010-01-07

Agonist antibody to human thrombopoietin receptor

#23
20090312526
2009-12-17

Method for producing antibodies

#24
20090142356
2009-06-04

Pharmaceutical composition of F(ab′)antibody fragments and a process for the preparation thereof

#25
20090123421
2009-05-14

ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS

#26
20090117043
2009-05-07

Antibodies That Specifically Bind to Neurokinin B

#27
20090028870
2009-01-29

Treatment of hematologic disorders

#28
20080085280
2008-04-10

Monovalent ligand of the FcαRI receptor as an anti-inflammatory agent

#29
20070224654
2007-09-27

Method of detecting an antibody in a liquid sample

#30
20070154471
2007-07-05

Method for generating F(ab′)2 antibody fragments

#31
20070141047
2007-06-21

Feline immunoglobulin E molecules and related methods

#32
20070020192
2007-01-25

Receptor specific transepithelial transport of therapeutics

#33
20060025573
2006-02-02

Reducing the immunogenicity of fusion proteins

#34
20050287150
2005-12-29

Antibodies against toxins and uses thereof

#35
20050281811
2005-12-22

Anti-lymphotoxin-β receptor antibodies as anti-tumor agents

#36
20050239151
2005-10-27

Method of detecting an antibody in a liquid sample

#37
20050214308
2005-09-29

Treatment of complement-associated disorders

#38
20050208596
2005-09-22

Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof

#39
20050163777
2005-07-28

Antibodies that specifically bind to neurokinin B

#40
20050054007
2005-03-10

Specific binding proteins including antibodies which bind to the necrotic centre of tumours, and uses thereof